To determine whether cilengitide further enhances anti-PD1 therapy-mediated T cell cytotoxic activity in a murine melanoma model, we collected tumor and spleen tissues to analyze T cell infiltration and function at 21 days after treatment. The gene discussed is PDCD1; the disease is neoplasm.